View Older Stories View More Recent Stories

Oct 3, 2018 06:10AM Gilead Sciences (GILD) Announces Hong Kong Department of Health Approval for Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide)
Oct 3, 2018 04:34AM Hong Kong Department of Health Approves Biktarvy(R) (bictegravir, emtricitabine, tenofovir alafenamide)
Sep 24, 2018 08:31AM Gilead Sciences (GILD) Subsidiary to Launch Authorized Generics of Epclusa and Harvoni
Sep 24, 2018 08:30AM Gilead Subsidiary to Launch Authorized Generics of Epclusa® (Sofosbuvir/Velpatasvir) and Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C
Sep 12, 2018 08:33AM Gilead Sciences (GILD) Reports Collaboration with Precision BioSciences to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing
Sep 12, 2018 08:31AM Gilead Sciences and Precision BioSciences Announce Collaboration to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing
Aug 30, 2018 04:01PM Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 12
Aug 28, 2018 05:00PM Gilead Sciences Appoints Laura Hamill as Executive Vice President, Worldwide Commercial Operations
Aug 27, 2018 06:36AM Gilead (GILD) Announces Yescarta Receives European Marketing Authorization for Treatment of R/R DLBCL and PMBCL
Aug 27, 2018 06:34AM Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy
Aug 14, 2018 05:01PM Gilead Sciences (GILD) Chief Medical Officer Andrew Cheng to Leave
Aug 14, 2018 05:00PM Gilead Sciences Announces Executive Promotions
Aug 7, 2018 08:16AM Express Scripts (ESRX) Announces 2019 National Preferred Formulary Exclusion List Changes
Aug 6, 2018 06:11AM Gilead Sciences (GILD) Reports Chinese (CNDA) Approval of Genvoya (Elvitegravir, Cobicistat, Emtricitabine & Tenofovir Alafenamide) for Treatment of HIV-1 Infection
Aug 6, 2018 06:09AM China National Drug Administration Approves Gilead’s Genvoya® (Elvitegravir, Cobicistat, Emtricitabine and Tenofovir Alafenamide), a Single Tablet Regimen for the Treatment of HIV-1 Infection
Jul 25, 2018 04:02PM Gilead Sciences Announces Third Quarter 2018 Dividend
Jul 25, 2018 04:01PM Gilead Sciences (GILD) CEO John F. Milligan to Step Down
Jul 25, 2018 04:00PM Gilead Sciences Announces CEO John F. Milligan to Step Down
Jul 24, 2018 08:05AM Gilead Sciences (GILD) Reports New Data on the Impact of Truvada (Emtricitabine and Tenofovir Disoproxil Fumarate)
Jul 24, 2018 08:00AM Gilead Announces New Data on the Impact of Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Pre-Exposure Prophylaxis (PrEP) on the Number of HIV Diagnoses in the United States
Jul 13, 2018 04:01PM Gilead Sciences to Release Second Quarter 2018 Financial Results on Wednesday, July 25, 2018
Jul 9, 2018 04:30PM Michael Amoroso to Join Kite as Senior Vice President and Head of Worldwide Commercial, Cell Therapy
Jun 29, 2018 07:56AM Gilead Sciences (GILD) Reports Positive Opinion from European CHMP for Yescarta (axicabtagene ciloleucel)
Jun 29, 2018 07:54AM European CHMP Adopts Positive Opinion for Yescarta® (axicabtagene ciloleucel) for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy
Jun 25, 2018 08:04AM Gilead Sciences (GILD) Announces EC Granted Marketing Authorization for its Biktarvy for Treatment of HIV-1 Infection
Jun 25, 2018 08:03AM European Commission Grants Marketing Authorization for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
Jun 11, 2018 08:30AM Gilead Sciences’ Chief Scientific Officer John McHutchison Appointed Officer of the Order of Australia
Jun 4, 2018 05:01PM Gilead Sciences (GILD) Names Andrew Dickinson Promoted to EVP, Corporate Development and Strategy; Martin Silverstein to Leave
Jun 4, 2018 05:00PM Gilead Sciences Announces Leadership Changes in Corporate Development and Strategy
Jun 4, 2018 09:01AM Kite (GILD) Announces Initial Results From a Phase 1 Study of TCR Cell Therapy in HPV-16-Positive Solid Tumors
Jun 4, 2018 09:00AM Kite Announces New Data Analyses for CAR T Therapy in Patients with Blood Cancers at the 2018 American Society of Clinical Oncology Meeting
Jun 4, 2018 09:00AM Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors
May 30, 2018 04:01PM Gilead Sciences to Present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13
May 30, 2018 05:53AM Gilead Sciences (GILD) Reports Chinese Approval of Epclusa (Sofosbuvir/Velpatasvir)
May 30, 2018 01:00AM China Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir), Gilead’s Pan-Genotypic Treatment for Chronic Hepatitis C Virus Infection
May 23, 2018 04:01PM Gilead Sciences to Present at the Jefferies 2018 Healthcare Conference on Wednesday, June 6
May 15, 2018 11:05AM Gilead Sciences (GILD) Says FDA Approves Expanded Indication for Truvada for Reducing the Risk of Acquiring HIV-1 in Adolescents
May 15, 2018 10:59AM U.S. Food and Drug Administration Approves Expanded Indication for Truvada® (Emtricitabine and Tenofovir Disoproxil Fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents
May 15, 2018 08:30AM Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline
May 9, 2018 04:48PM Gilead Sciences (GILD) Appoints Harish M. Manwani to Board
May 9, 2018 04:30PM Harish Manwani Joins Gilead Sciences’ Board of Directors
May 8, 2018 09:00AM Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 16
May 1, 2018 04:02PM Gilead Sciences Announces Second Quarter 2018 Dividend
Apr 30, 2018 04:05PM Gilead and Verily Announce Scientific Collaboration to Identify and Understand Immunological and Molecular Drivers of Inflammatory Diseases
Apr 27, 2018 06:37AM Gilead Sciences (GILD) Reports European CHMP Adopts Positive Opinion for Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide)
Apr 27, 2018 06:36AM European CHMP Adopts Positive Opinion for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide)
Apr 17, 2018 05:00PM Gilead Sciences to Release First Quarter 2018 Financial Results on Tuesday, May 1, 2018
Apr 13, 2018 10:16AM Gilead (GILD) Presents Data on Multiple Investigational Regimens for Treatment of NASH and Advanced Fibrosis at The International Liver Congress
Apr 13, 2018 10:15AM Gilead Presents Data on Multiple Investigational Regimens for the Treatment of Patients With Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis at The International Liver Congress™ 2018
Mar 12, 2018 09:10AM Gilead (GILD) Says Norbert Bischofberger, PhD, to Step Down; John McHutchison, MD, Appointed Chief Scientific Officer and Andrew Cheng, MD, PhD, Appointed Chief Medical Officer
View More Recent Stories View Older Stories